DGAP-News: Neovacs S.A. / Key word(s): Miscellaneous
NEOVACS REALIGNS SCIENTIFIC ADVISORY BOARD TO SUPPORT SHIFT IN
THERAPEUTIC FOCUS
03.02.2015 / 08:00
---------------------------------------------------------------------
PRESS RELEASE
NEOVACS REALIGNS SCIENTIFIC ADVISORY BOARD TO SUPPORT SHIFT IN THERAPEUTIC
FOCUS
SAB chairman Jacques Banchereau, PharmD, Ph.D. to join Neovacs Board of
Directors
Paris, February 3, 2015 - NEOVACS (Alternext Paris : ALNEV), a leader in
active immunotherapies for the treatment of autoimmune diseases, today
announced that new members have joined the Company's Scientific Advisory
Board (SAB). Current SAB chairman, Prof. Jacques Banchereau, PharmD, Ph.D.
will also join Neovacs' Board of Directors.
Neovacs formed a scientific committee comprised of leaders in immune
therapy, chronic inflammatory and autoimmune diseases in October 2014 with
the goal of strengthening the Company's scientific base and increasing
international visibility of its innovative technology in the treatment of
autoimmune diseases.
Recent enhancements to Neovacs' SAB reflect the change in the Company's
pipeline, with a greater emphasis on pathologies targeted by IFNα-Kinoid
and VEGFα-Kinoid. Professor Banchereau will remain SAB chairman.
"The new members of the Scientific Advisory Board bring high-level
experience in onco-immunology, neuro-immunology and ophthalmology to
Neovacs. We are grateful for their participation and look forward to their
expert analysis and guidance regarding our clinical and preclinical
portfolio," said Miguel Sieler, Chief Executive Officer of Neovacs. "We
are also very proud to announce that Professor Banchereau has agreed to
join our Board of Directors. As a Director, Jacques will play an even
greater role in the strategic direction of the Company, including the
development of Neovacs' Kinoid technology."
SAB members include:
Prof. Jacques Banchereau, PharmD, Ph.D. (Chairman)
Professor and Director of Immunological Sciences
Jackson Laboratory for Genomic Medicine, Famington, Conn.
Prof. Betty Diamond, M.D.
Investigator & Head of Center for Autoimmune and Musculoskeletal Diseases,
The Feinstein Institute for Medical Research; Professor of Molecular
Biology and Medicine, Hofstra North Shore-LIJ School of Medicine,
Manhasset, N.Y.
Prof. Napoleone Ferrara, M.D.
Professor of Ophthalmology and Pathology
Univeristy of California at San Diego - La Jolla, Calif.
Prof. Steve A Greenberg, M.D.
Department of Neurology, Brigham and Women's Hospital and Children's
Hospital Informatics Program, Harvard Medical School and Harvard-MIT
Division of Health Sciences and Technology, Boston
Prof. Bernard Lauwerys, M.D., Ph.D.
Professor of Rheumatology
Cliniques Universitaires Saint Luc & Université Catholique de Louvain,
Brussels, Belgium
Prof. Miriam Merad, M.D., Ph.D.
Professor of Oncological Sciences and Medicine
Tisch Cancer Institute at The Mount Sinai Health System, New York, N.Y.
Prof. Virginia Pascual, M.D., Ph.D.
Director, Center for Inflammation and Autoimmune Diseases
Baylor Institute for Immunology Research, Dallas, Texas
Laurence Zitvogel, M.D.
Research Director at INSERM U1015, Gustave Roussy Cancer Center, Villejuif,
France
The first meeting of the new SAB will be held in New York City on Feb. 12,
2015. Members will discuss the results of Neovacs' phase IIb study of
TNF-Kinoid in Rheumatoid Arthritis and a path forward for this research
program. Members will also finalize the development plan for Neovacs'
IFNα-Kinoid therapeutic, including the upcoming clinical trials in lupus
and potentially other indications.
The SAB will meet again in mid-2015 to discuss a development plan for
VEGF-Kinoid, Neovacs' preclinical therapeutic candidate targeting
Age-related Macular Degeneration and solid tumors.
About Neovacs
Created in 1993, Neovacs is today a leading biotechnology company focused
on an active immunotherapy technology platform (Kinoids) with applications
in autoimmune and/or inflammatory diseases. On the basis of the company's
proprietary technology for inducing a polyclonal immune response (covered
by five patent families that potentially run until 2032) Neovacs is
focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy
being developed for the indication of lupus. Neovacs is also conducting
preclinical development works on other therapeutic vaccines in the fields
of auto-immune diseases, oncology and allergies. The goal of the Kinoid
approach is to enable patients to have access to safe treatments with
efficacy that is sustained in these life-long diseases.
For more information on Neovacs, visit www.neovacs.fr
Contacts
Neovacs
Nathalie Trépo
+33 (0)1 53 10 93 00
ntrepo@neovacs.com
Publicis
Stéphanie Tabouis
Aubane de Gelis
+33 (0)1 44 82 46 38
aubane.de-gelis@consultants.publicis.fr
Investor Relations - Financial Communications Germany - MC Services
Raimund Gabriel
+49-89-210228-30
raimund.gabriel@mc-services.eu
Press - U.S. Inquiries - The Ruth Group
Melanie Sollid-Penton
1.646.536.7023
msollid@theruthgroup.com
---------------------------------------------------------------------
03.02.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Neovacs S.A.
3-5, Impasse Reille
75014 Paris
France
Phone: +33 (0)1 53 10 93 00
Fax: +33 (0)1 53 10 93 03
E-mail: www.neovacs.fr
Internet: info@neovacs.fr
ISIN: FR0004032746
WKN: A1CVKR
Listed: Freiverkehr in Stuttgart; Frankfurt in Open Market
End of News DGAP News-Service
---------------------------------------------------------------------
318695 03.02.2015
DGAP-News: NEOVACS REALIGNS SCIENTIFIC ADVISORY BOARD TO SUPPORT SHIFT IN THERAPEUTIC FOCUS
| Source: EQS Group AG